



AM Notice: AM 2019/19 Date of Issue: 11/2018

Analysis Method Notice

Total antibacterial items per 1,000 STAR-PUs

This notice describes an Analysis Method that has been developed for use in the production of published national outcome indicators, performance measures and/or currencies, which are derived directly from NHS Wales data.

The Analysis Method has been reviewed by the Analysis Methodologies Group and its output submitted to the Welsh Information Standards Board (WISB) for potential accreditation.

It should be noted that, where the data flow on which the analysis is being undertaken has not been reviewed by WISB (see 'Status of WISB Data Standards Assurance' below), accreditation of the analysis method **cannot** be interpreted as an approval of the underlying data standards or the quality of the data used.

It is recognised that formal review and/or assurance of the data flow may have been undertaken by other bodies, where those data are being formally published; for example, as Official Statistics'. In such circumstances, users of this method are advised to contact the relevant organisations should they require further information on the underlying quality of the specified data source.

For further details about the group, including Terms of Reference and membership, please visit the following website:

http://howis.wales.nhs.uk/sites3/page.cfm?orgid=742&pid=56696

WISB Reference: ISRN 2018 / 002

Please address enquiries about this Analysis Method the NHS Wales Informatics Service Data Standards Team.

E-mail: data.standards@wales.nhs.uk / Tel: 029 2050 2539

AM Notice 2018/01 Page 1 of 8

WISB Analysis Method Appraisal Assessment	Accredited This Analysis Method has been appraised by WISB and is felt to: • Meet the specified indicator requirement, in that it is suitable for its calculation / derivation; • Is reproducible by organisations, where appropriate.
WISB Analysis Method Appraisal Outcome(s)	

Status of Data Standards Assurance	WISB Reviewed The data used in this Analysis Method are based on data item standards that have been through the Information Standards Assurance Process.
WISB Decision	Approved
Data Standards Assurance Outcome(s)	

AM Notice 2018/01 Page 2 of 8

Indicator Total antibacterial items per 1,000 STAR-PUs
Target: 4 quarter reduction trend
Rationale / Context The widespread and often excessive use of antimicrobials is one of the main factors contributing to the increasing emergence of antimicrobial resistance, resulting in many common and life threatening infections becoming difficult (or even impossible) to treat.
Data Source(s)
Alll Wales Therapeutic and Toxicology Centre National Prescribing Indicators 2017-2018
Definitions:
Definitional Guidance:
Data Items:

Detailed Specification

n/a

n/a

Terms:

Data derives from GP prescriptions (WP10s) that are dispensed in community pharmacies and by dispensing doctors and recoded on the NHS Shared Services Database – Comparative Analysis System for Prescribing Audit (CASPA). CASPA provides a record of all WP10 prescriptions (issued by GPs in Wales for patients receiving NHS treatment) forwarded to Prescribing Services, NWSSP, for processing and payment following dispensing.

Data is based on dispensing in the community for items prescribed in general practices only. Accurate prescribing data is currently only available for primary care. It is not currently possible to measure prescribing data in the same way for secondary care.

Data is presented on an all Wales and Health Board basis. It is also available at practice, cluster and unitary authority levels.

Data is collected based on the GP practice address for the prescription.

Comparative trends for antibiotic indicators should be interpreted with caution, with a particular respect to seasonal variation.

Numerator: Is purely the number of items dispensed, with no adjustment for age and sex of patient.

Page 3 of 8

Denominator:

Specific Therapeutic Group Age-Sex Related Prescribing Units (STAR-PU)

This measures prescribing weighted for age and sex of patients. There are differences in the age and sex of patients for whom medicines in specific therapeutic groups are usually prescribed. STAR-PU has been developed based on costs of prescribing items within the therapeutic groups.

Further information on STAR-PU is available at the Health and Social Care Information Centre (HSCIC) website: http://www.hscic.gov.uk/prescribing/measures

STAR-PU IS used to benchmark with the Medicines Optimisation Key Therapeutic Topics comparators in England. Data is comparable with English CCGs.

STAR-PU calculations are available through NHS Wales Shared Services Partnership: Primary Care Services.

The full list of antibacterial items monitored for this measure is included in Additional Information.

Calculation:

Numerator

The number of calls to the DAN 24/7 helpline (drug and alcohol) by Welsh residents at health board area level

Denominator

Mid-year population estimate

Reporting Format / Frequency

Reporting Frequency	Quarterly
Time Delay of Reported Data?	4 months (e.g. the report for Q3 is due April)

Discussion Points / Areas for Future Development

This section details any areas the Analysis Methodologies Group felt needed further consideration / review by the 'owner' of the method.

Page 4 of 8

Appendix A - Additional Information

Antibacterial items monitored for this measure

BNF Code	Description
0501011	Benzylpenicillin&phenoxymethylpenicillin
0501011 0501011P0	Phenoxymethylpenicillin (penicillin V)
050101110	Benzylpenicillin Sodium (penicillin G)
050101150 0501011F0	Benzathine Penicillin
0501011	Penicillinase-Resistant Penicillins
0501012 0501012G0	Flucloxacillin Sodium
0501012H0	Flucloxacillin Magnesium
0501013	Broad-Spectrum Penicillins
0501013 0501013B0	Amoxicillin
0501013K0	Co-Amoxiclav (amoxicillin/clavul Acid)
0501013L0	Co-Fluampicil(flucloxacillin/ampicillin)
0501013E0	Ampicillin
0501013C0	Amoxicillin Sodium
0501014	Antipseudomonal Penicillins
0501014 0501014S0	Piperacillin Sodium/tazobactam Sodium
0501015	Mecillinams
0501015 0501015P0	Pivmecillinam Hydrochloride
0501015H0	Mecillinam
0501020	Cephalosporins,cephamycins & Betalactams
0501020R0	Cefalexin
0501020R0	Cefaclor
0501020W0	Cefradine
0501020Q0	Cefuroxime Axetil
0501020K0	Ceftriaxone Sodium
050102010	Meropenem
0501020L0	Ceftazidime Pentahydrate
0501020E0	Cefixime
0501020AB	Ertapenem Sodium
0501020D0	Cefadroxil
0501020F0	Cefotaxime Sodium
0501020P0	Cefuroxime Sodium
050102010	Cefpodoxime
0501020X0	Imipenem With Cilastatin
0501021	Cephalosporins
0501021A0	Cefaclor
0501021L0	Cefalexin
0501021D0	Cefotaxime Sodium
0501022	Carbanpenems
0501022A0	Meropenem
0501023	Other Beta-Lactam Antibiotics
0501023A0	Aztreonam
0501030	Tetracyclines
0501030L0	Lymecycline

AM Notice 2018/01 Page 5 of 8

BNF Code	Description
0501030I0	Doxycycline Hyclate
0501030T0	Oxytetracycline
0501030P0	Minocycline Hydrochloride
0501030F0	Demeclocycline Hydrochloride
0501030V0	Tetracycline
0501030Y0	Tigecycline
0501040	Aminoglycosides
0501040U0	Tobramycin
0501040H0	Gentamicin Sulfate
0501040N0	Neomycin Sulfate
0501040C0	Amikacin
0501040P0	Paromomycin Sulphate
0501050	Macrolides
0501050A0	Azithromycin
0501050B0	Clarithromycin
0501050C0	Erythromycin
0501050H0	Erythromycin Ethylsuccinate
0501050N0	Erythromycin Stearate
0501050T0	Telithromycin
0501050F0	Erythromycin Estolate
0501060	Clindamycin And Lincomycin
0501060D0	Clindamycin Hydrochloride
0501060E0	Clindamycin Phosphate
0501070	Some Other Antibiotics
050107010	Colistimethate Sodium
0501070X0	Rifaximin
0501070N0	Sodium Fusidate
0501070U0	Vancomycin Hydrochloride
0501070W0	Linezolid
0501070ACAA	Fidaxomicin
0501070T0	Teicoplanin
0501070F0	Chloramphenicol
0501070M0	Fusidic Acid
0501070H0	Colistin Sulphate
0501080	Sulphonamides And Trimethoprim
0501080W0	Trimethoprim
0501080D0	Co-Trimoxazole(trimethoprim/sulfamethox
0501080V0	Sulfapyridine
0501080J0	Sulfadiazine
0501080T0	Sulfamethoxypyridazine
0501090	Antituberculous Drugs
0501090R0	Rifampicin
0501090H0	Ethambutol Hydrochloride
0501090K0	Isoniazid
0501090N0	Pyrazinamide
0501090S0	Rifampicin Combined Preparations

AM Notice 2018/01 Page 6 of 8

BNF Code	Description
0501090Q0	Rifabutin
050109010	Ethionamide
0501100	Antileprotic Drugs
0501100C0	Clofazimine
0501100H0	Dapsone
0501100J0	Thalidomide (antileprotic)
0501110	Metronidazole, Tinidazole & Ornidazole
0501110C0	Metronidazole
0501110G0	Tinidazole
0501120	Quinolones
0501120L0	Ciprofloxacin
0501120N0	Nalidixic Acid
0501120P0	Ofloxacin
0501120Q0	Norfloxacin
0501120X0	Levofloxacin
0501120Y0	Moxifloxacin
0501130	Urinary-Tract Infections
0501130D0	Fosfomycin Trometamol
0501130H0	Methenamine Hippurate
0501130R0	Nitrofurantoin
0501130S0	Fosfomycin Calcium

Appendix B – SQL Code (where applicable)			
n/a			

AM Notice 2018/01 Page 8 of 8